Milind Thatte is Merck's New MD
Drug firm Merck Ltd. has announced that Mr. Milind Thatte has been appointed as Managing Director of the company effective from April 1, 2018. The company’s board appointed Mr. Thatte, General Manager Healthcare, as an Additional Director and Managing Director of the company, in place of Mr. Anand Nambiar, Merck informed in a stock exchange filing. Earlier Mr. Thatte headed the healthcare business of India and frontier markets. He heads the leadership team of healthcare sector and is the member of the country council of Merck India, the company informed.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-28
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Merck Establishes New Semiconductor Hub in Taiwan
-
Merck Completes Sale of Surface Solutions Business to GNMI for €665 Million
-
Merck and Siemens Collaborate on Smart Manufacturing
-
Merck sells Surface Solutions to Global New Material International for €665 million in cash
-
Merck Group acquires chip equipment supplier Unity-SC for €155 million
-
Merck Launches Commercial Production of First GMP-Compliant Cell Culture Media Production Line in China
-
Merck to acquire EyeBio for $3 billion
-
Circa signs OEM agreement with Merck to supply and sell Cyrene
-
The Rising Heat of DAC Drugs: ADC and PROTAC Sparking Innovation
-
Merck Expands Biosafety Testing Laboratory Center in Shanghai
Recommend Reading
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
Post-holiday, China's propylene oxide market surges and then stabilizes
-
Short-term Costs and Demand Both Driving Melamine Prices to Stay Stable and Improve
-
February Ammonium Sulfate Market Continues to Rise in China
-
Nouryon Doubles Triethylaluminum Co-catalyst Capacity in China and Makes Several Major Investments
-
Cyclohexane market prices mainly remain stable in China